(19)
(11) EP 1 907 000 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.07.2013 Bulletin 2013/29

(45) Mention of the grant of the patent:
17.10.2012 Bulletin 2012/42

(21) Application number: 06784684.0

(22) Date of filing: 08.06.2006
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
(86) International application number:
PCT/US2006/022423
(87) International publication number:
WO 2006/133396 (14.12.2006 Gazette 2006/50)

(54)

Methods and compositions for the treatment of persistent HIV infections by inhibiting the programmed cell death 1 (PD-1) pathway

Verfahren und Zusammensetzungen zur Behandlung persistenter HIV-infektion mittels Hemmung des programmierten 1 (pd-1)-Zelltodweges

Procédés et compositions pour le traitement d'infections persistantes à vih en inhibant la voie de la mort cellulaire programmée (pd-1)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 08.06.2005 US 688872 P

(43) Date of publication of application:
09.04.2008 Bulletin 2008/15

(60) Divisional application:
11162667.7 / 2397155
11162681.8 / 2397156

(73) Proprietors:
  • DANA-FARBER CANCER INSTITUTE
    Boston, MA 02115 (US)
  • The Brigham and Women's Hospital, Inc.
    Boston, MA 02215 (US)
  • Emory University
    Atlanta, GA 30322 (US)
  • President and Fellows of Harvard College
    Cambridge, MA 02138 (US)

(72) Inventors:
  • FREEMAN, Gordan
    Brookline, MA 02445 (US)
  • SHARPE, Arlene
    Brookline, MA 02445 (US)
  • DORFMAN, David, M.
    Brookline, MA 02445 (US)
  • AHMED, Rafi
    Atlanta, GA 30307 (US)
  • BARBER, Daniel
    Rockville, MD 20852 (US)
  • WHERRY, E., John
    Havertown, Pennsylvania 19083 (US)

(74) Representative: Donald, Jenny Susan et al
Forresters Skygarden Erika-Mann-Strasse 11
80636 München
80636 München (DE)


(56) References cited: : 
WO-A-2004/004771
WO-A2-02/00730
 WO-A-2004/056875
   
  • HIRANO FUMIYA ET AL: "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity." CANCER RESEARCH 1 FEB 2005, vol. 65, no. 3, 1 February 2005 (2005-02-01), pages 1089-1096, XP002419626 ISSN: 0008-5472
  • IWAI YOSHIKO ET AL: "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 19, 17 September 2002 (2002-09-17), pages 12293-12297, XP002398159 ISSN: 0027-8424
  • TRABATTONI DARIA ET AL: "B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression." BLOOD 1 APR 2003, vol. 101, no. 7, 1 April 2003 (2003-04-01), pages 2514-2520, XP002419628 ISSN: 0006-4971
  • BARBER DANIEL L ET AL: "Restoring function in exhausted CD8 T cells during chronic viral infection." NATURE 9 FEB 2006, vol. 439, no. 7077, 9 February 2006 (2006-02-09), pages 682-687, XP002419629 ISSN: 1476-4687
  • HE LANXIANG ET AL: "Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma." ANTICANCER RESEARCH 2005 SEP-OCT, vol. 25, no. 5, September 2005 (2005-09), pages 3309-3313, XP009078741 ISSN: 0250-7005
  • BLANK CHRISTIAN ET AL: "Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy." CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII APR 2005, vol. 54, no. 4, April 2005 (2005-04), pages 307-314, XP002419627 ISSN: 0340-7004
  • OHIGASHI YUICHIRO ET AL: "Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 APR 2005, vol. 11, no. 8, 15 April 2005 (2005-04-15), pages 2947-2953, XP002419631 ISSN: 1078-0432
  • VELU VIJAYAKUMAR ET AL: "Enhancing SIV-specific immunity in vivo by PD-1 blockade.", NATURE 12 MAR 2009 LNKD- PUBMED:19078956, vol. 458, no. 7235, 12 March 2009 (2009-03-12), pages 206-210, ISSN: 1476-4687
  • HA SANG-JUN ET AL: "Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection.", THE JOURNAL OF EXPERIMENTAL MEDICINE 17 MAR 2008 LNKD- PUBMED:18332181, vol. 205, no. 3, 17 March 2008 (2008-03-17), pages 543-555, ISSN: 1540-9538
  • HIRANO FUMIYA ET AL: "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 3, 1 February 2005 (2005-02-01), pages 1089-1096, XP002419626, ISSN: 0008-5472
  • FAHEY J L ET AL: "Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements.", AIDS (LONDON, ENGLAND) 10 SEP 1998 LNKD- PUBMED:9764776, vol. 12, no. 13, 10 September 1998 (1998-09-10), pages 1581-1590, ISSN: 0269-9370
  • WEISS L ET AL: "Restoration of normal interleukin-2 production by CD4+ T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy.", THE JOURNAL OF INFECTIOUS DISEASES OCT 1999 LNKD- PUBMED:10479131, vol. 180, no. 4, October 1999 (1999-10), pages 1057-1063, ISSN: 0022-1899
  • LATCHMAN YVETTE ET AL: "PD-L2 is a second ligand for PD-1 and inhibits T cell activation", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 2, no. 3, 1 March 2001 (2001-03-01), pages 261-268, XP001064842, ISSN: 1529-2908, DOI: 10.1038/85330
  • MACHUCA A ET AL: "Human immunodeficiency virus type 2 infection in Spain. The HIV-2 Spanish Study Group.", INTERVIROLOGY 1999 LNKD- PUBMED:10393502, vol. 42, no. 1, 1999, pages 37-42, ISSN: 0300-5526
  • TORZEWSKI MICHAEL ET AL: "No effect of C-reactive protein on early atherosclerosis in LDLR-/- / human C-reactive protein transgenic mice.", THROMBOSIS AND HAEMOSTASIS JAN 2008 LNKD- PUBMED:18217154, vol. 99, no. 1, January 2008 (2008-01), pages 196-201, ISSN: 0340-6245
  • REIFENBERG KURT ET AL: "Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer?", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY AUG 2005 LNKD- PUBMED:15920030, vol. 25, no. 8, August 2005 (2005-08), pages 1641-1646, ISSN: 1524-4636
  • TAVEL JORGE A ET AL: "Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.", PLOS ONE 2010 LNKD- PUBMED:20186278, vol. 5, no. 2, 2010, page e9334, ISSN: 1932-6203
  • BAGASRA O ET AL: "The role of CD8-positive lymphocytes in the control of HIV-1 infection of peripheral blood mononuclear cells.", IMMUNOLOGY LETTERS FEB 1993 LNKD- PUBMED:8509156, vol. 35, no. 2, February 1993 (1993-02), pages 83-92, ISSN: 0165-2478
  • MEIRELES-DE-SOUZA L R ET AL: "Therapeutic role of CD8+ T cells in HIV-1 infection: targets and suppressors of viral replication.", EXPERT OPINION ON BIOLOGICAL THERAPY MAR 2005 LNKD- PUBMED:15833070, vol. 5, no. 3, March 2005 (2005-03), pages 321-332, ISSN: 1744-7682
  • TRION A ET AL: "No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY AUG 2005 LNKD- PUBMED:15920036, vol. 25, no. 8, August 2005 (2005-08), pages 1635-1640, ISSN: 1524-4636
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).